Why Palisade Bio, Inc.’s (PALI) Stock Is Down 9.20%
As of Thursday, November 05, Palisade Bio, Inc.’s PALI share price has dipped by 9.20%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Commentary & Analysis
Why Palisade Bio, Inc.’s (PALI) Stock Is Up 8.93%
As of Tuesday, November 03, Palisade Bio, Inc.’s PALI share price has surged by 8.93%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Palisade Bio, Inc.’s (PALI) Stock Is Up 8.58%
As of Tuesday, October 20, Palisade Bio, Inc.’s PALI share price has surged by 8.58%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Palisade Bio, Inc.’s (PALI) Stock Is Down 5.12%
As of Wednesday, October 14, Palisade Bio, Inc.’s PALI share price has dipped by 5.12%, which has investors questioning if this is right time to buy.Michael Rose
Why Palisade Bio, Inc.’s (PALI) Stock Is Down 5.35%
As of Tuesday, October 13, Palisade Bio, Inc.’s PALI share price has dipped by 5.35%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | PALI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $196.9 | $219.9 | 28% |
|
| Shares Out (Mil) | 211.4 | 54.1 | 77% |
|
| Institutional Ownership | 97.2% | 92.9% | 73% |
|
| Float (Mil) | 135.4 | 41.4 | 66% |
|
| Beta | 1.54 | 0.95 | 83% |
|
| Avg Daily Volume (000s) | 5,780 | 522 | 92% |
|
| Price Change (52-week) |
(32.7%) | 44.7% | 28% |
|
| Growth | PALI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (10.3%) | (10.1%) | 29% |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($0.061) | ($0.224) | ($0.284) | |
| Month Ago EPS | ($0.061) | ($0.226) | ($0.280) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.061) | ($0.239) | ($0.286) | |
| Year/Year Chg | 22.0% | (25.6%) | 14.6% | |
| Financials | PALI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $38 | 1% |
|
| Net Income (TTM) (Mil) | ($32) | ($44) | 20% |
|
| EPS (TTM) | ($0.201) | ($1.500) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($18) | ($35) | 16% |
|
| Net Cash Flow (TTM) (Mil) | na | $0 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $248 | $166 | 28% |
|
| Valuation | PALI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.61 | 2.06 | 46% |
|
| P/E | na | 16.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | PALI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 67.3% | 96% |
|
| Net Margin | na | (61.0%) | na |
|
| ROA | (47.7%) | (47.5%) | 12% |
|
| ROE | (51.4%) | (52.7%) | 15% |
|
| Liabilities to Assets | 4.4% | 29.6% | 2% |
|
| F-Score | 3 | 3 | 18% |
|
Palisade Bio, Inc. did not pass any screens on 11/6/2026.
